LEADER 00815nam0-22003011i-450- 001 990002011510403321 005 20040618092012.0 035 $a000201151 035 $aFED01000201151 035 $a(Aleph)000201151FED01 035 $a000201151 100 $a20030910d1951----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $ay---j---001yy 200 1 $aLaboratory manual of parasitology$fJames E. Ackert 210 $aMinneapolis (Minnesota)$cBurgess$d1951 215 $a63 p.$d27 cm 610 0 $aParassitologia 676 $a616.96 700 1$aAckert,$bJames E.$085130 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002011510403321 952 $a61 III D.4/35$b1113$fDAGEN 959 $aDAGEN 996 $aLaboratory manual of parasitology$9402365 997 $aUNINA LEADER 04674nam 22006495 450 001 9910409697903321 005 20250609111356.0 010 $a3-030-33668-9 024 7 $a10.1007/978-3-030-33668-4 035 $a(CKB)4100000011204650 035 $a(MiAaPQ)EBC6183674 035 $a(DE-He213)978-3-030-33668-4 035 $a(PPN)243758456 035 $a(MiAaPQ)EBC6183658 035 $a(EXLCZ)994100000011204650 100 $a20200424d2020 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aLipid Signaling in Human Diseases /$fedited by Julian Gomez-Cambronero, Michael A. Frohman 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (xiv, 336 pages) 225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v259 311 08$a3-030-33667-0 327 $aPart 1. New Roles for Sphingolipid Signaling and Cell Function -- 1. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma -- 2. Exploring the Therapeutic Landscape of Sphingomyelinases -- 3. Sphingosine kinases as druggable targets -- Part 2. Phospholipase D and Mitogen Phosphatidic Acid in Human Disease -- 4. Prospects for PLD inhibition in cancer and thrombotic disease -- 5. Phospholipase D and the Mitogen Phosphatidic Acid in Human Disease: Inhibitors of PLD at the Crossroads of Phospholipid Biology and Cancer -- 6. Role of Phospholipase D-Derived Phosphatidic Acid in Regulated Exocytosis and Neurological Disease -- Part 3. Lipid Kinases and Novel Regulatory Pathways -- 7. Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors -- 8. Functions of Nuclear Polyphosphoinositides -- Part 4. Bioactive Lipids in Health and Disease -- 9. Platelet-Activating Factor as an Effector for Environmental Stressors -- 10. Phospholipase D and Choline Metabolism -- Part 5- Lipids and Membrane Microdomains -- 11. Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology -- 12. Lipids and Membrane Microdomains: The Glycerolipid and Alkylphosphocholine Class of Cancer Chemotherapeutic Drugs -- Part 6. Nuclear Trafficking of Lipids -- 13. Inositide-Dependent Nuclear Signalling in Health and Disease -- 14. Lipids in Exosome Biology. 330 $aLipids are an integral part of cell membrane architecture, are intermediaries in cell metabolism, and are involved in transmitting cell signals from hormones, growth factors and nutrients. A number of lipases and phospholipases, lipid kinases, lipid phosphatases, sphingosine kinases, and their reaction products have been implicated in fundamental cellular processes including cell proliferation, division and migration. These enzymes and their products underlie the molecular mechanisms of numerous human diseases, in particular metabolic disease (diabetes), cancer, neurodegenerative disease and cardiovascular disease. Over the last decade, studies have advanced to the point that a number of inhibitors for these enzymes have been developed to attempt to ameliorate these conditions; some of the inhibitors are currently in human clinical trial. The need for this book is to review the current status of this field and the prospect for the inhibitors to be clinically important. . 410 0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v259 606 $aPharmacology 606 $aCancer$xResearch 606 $aClinical biochemistry 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005 606 $aLípids$2thub 606 $aMalalties$2thub 608 $aLlibres electrònics$2thub 615 0$aPharmacology. 615 0$aCancer$xResearch. 615 0$aClinical biochemistry. 615 14$aPharmacology/Toxicology. 615 24$aCancer Research. 615 24$aMedical Biochemistry. 615 7$aLípids 615 7$aMalalties 676 $a612.01577 702 $aGomez-Cambronero$b Julian$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFrohman$b Michael A.$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910409697903321 996 $aLipid signaling in human diseases$91764242 997 $aUNINA